Alpha Tau Reports Positive Pancreatic Cancer Study Results, Highlighting Immune-Preservation and Disease Control
DRTS has more than doubled off its 52-week low of $2.3.
Summary
Alpha Tau Medical announced positive final results from its first-in-human pancreatic cancer study, demonstrating high disease control and an immune-preserving profile for its Alpha DaRT therapy. These findings support further development in this challenging indication.
Key Events · Product Development and Regulatory · DRTS
-
Positive Pancreatic Cancer Study Results
Final results from the first-in-human Montreal study for pancreatic ductal adenocarcinoma (PDAC) showed an 81% disease control rate (DCR) across 32 patients, improving to 87% when excluding initial low-dose patients.
-
Immune-Preserving Profile Demonstrated
The Alpha DaRT therapy demonstrated an immune-preserving profile and potential anti-inflammatory effects, which is unique compared to conventional radiation therapy and may support combination with other systemic therapies like immunotherapy.
-
Ongoing Clinical Development
The company is further exploring Alpha DaRT for PDAC in its U.S. multi-center IMPACT pilot study, evaluating its use in combination with chemotherapy for newly diagnosed unresectable locally advanced or metastatic pancreatic adenocarcinoma.
Analysis · DRTS · Industrial Applications And Services
Alpha Tau Medical's announcement of positive final results from its Montreal pancreatic cancer study is a significant development for its Alpha DaRT therapy. The reported 81% disease control rate (87% excluding initial low-dose patients) in pancreatic ductal adenocarcinoma (PDAC), a notoriously difficult-to-treat cancer, is encouraging. Crucially, the study highlighted Alpha DaRT's immune-preserving profile and potential anti-inflammatory effects, which differentiate it from conventional radiation therapies and could enable combination with immunotherapies. Investors should monitor the progress of the ongoing U.S. multi-center IMPACT trial, which is evaluating Alpha DaRT in combination with chemotherapy for newly diagnosed PDAC, as these early positive results provide a strong foundation for future clinical success and potential market approval.
How filings like this one have moved
In the 30 days to Sep 14, 2026, 35.8% of the 1045 measured filings Wiseek scored 8 moved their stock by 5% or more by the next session's close. The median move was -0.43%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, DRTS was trading at $5.25 on NASDAQ in the Industrial Applications And Services sector, with a market capitalization of approximately $445.1M. The 52-week trading range was $2.30 to $5.22. This filing was assessed with positive market sentiment and an importance score of 8 out of 10.